IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Abstract Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of
cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in …
cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in …
[HTML][HTML] Novel and emerging therapies for inflammatory bowel disease
B Al-Bawardy, R Shivashankar… - Frontiers in …, 2021 - frontiersin.org
Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are
chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic …
chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic …
Blockade of IL-23: What is in the Pipeline?
Abstract Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease
[CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The …
[CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The …
emerging drug therapies in inflammatory bowel disease
LB Grossberg, K Papamichael… - Alimentary …, 2022 - Wiley Online Library
Background The landscape of inflammatory bowel disease (IBD) treatment is rapidly
expanding with the development of new therapeutic options. Aim To review the mechanisms …
expanding with the development of new therapeutic options. Aim To review the mechanisms …
[HTML][HTML] An update for pharmacologists on new treatment options for inflammatory bowel disease: the clinicians' perspective
C Schmidt, PC Grunert, A Stallmach - Frontiers in Pharmacology, 2021 - frontiersin.org
The introduction of anti-tumor necrosis factor antibodies resulted in a considerable
expansion of the options available for the treatment of inflammatory bowel disease …
expansion of the options available for the treatment of inflammatory bowel disease …
Personalised medicine with IL-23 blockers: myth or reality?
ZS Gottlieb, BE Sands - Journal of Crohn's and Colitis, 2022 - academic.oup.com
Abstract Background and Aims The medical management of inflammatory bowel disease
[IBD] has become increasingly targeted, through the identification of specific immune …
[IBD] has become increasingly targeted, through the identification of specific immune …
IL-23 monoclonal antibodies for IBD: so many, so different?
Abstract Interleukin [IL]-23 is a member of the IL-12 family of cytokines and has been
implicated in multiple inflammatory disorders including psoriasis, psoriatic arthritis, and the …
implicated in multiple inflammatory disorders including psoriasis, psoriatic arthritis, and the …
Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data
AM Johnson, EV Loftus Jr - Expert Review of Gastroenterology & …, 2023 - Taylor & Francis
Introduction Risankizumab is a humanized monoclonal antibody that selectively inhibits
interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis …
interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis …
Updates in clinical, endoscopic, and histologic composite and Co-primary endpoints for clinical trials in inflammatory bowel disease
Purpose of review The evolution of endpoints used to assess disease activity and treatment
efficacy in inflammatory bowel disease (IBD) has accompanied changes in clinical trial …
efficacy in inflammatory bowel disease (IBD) has accompanied changes in clinical trial …
Novel Therapies for Inflammatory Bowel Disease
S Berera, GR Lichtenstein - Current Treatment Options in Gastroenterology, 2022 - Springer
Purpose of review Significant advances in the discovery of novel therapeutic targets for
inflammatory bowel disease address a crucial need for patients refractory to available …
inflammatory bowel disease address a crucial need for patients refractory to available …